Melanoma therapy: Check the checkpoints

Masutaka Furue, Takafumi Kadono

研究成果: ジャーナルへの寄稿評論記事

5 引用 (Scopus)

抄録

Recent mutational and translational studies have revealed that the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway plays a key role in melanomagenesis. Mutations in NRAS and BRAF are found in the majority of melanomas resulting in the formation of constitutively active NRAS and BRAF molecules, which leads to the proliferation and survival of melanoma cells through the activation of MEK/ERK signals. Inhibitors of BRAF or MEK significantly extend the progression-free survival and overall survival of melanoma patients compared with conventional chemotherapies. Combining BRAF and MEK inhibitors further enhances the clinical effectiveness. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is an immune checkpoint molecule that downregulates T-cell activation by binding to B7 (CD80/CD86) molecules on antigen-presenting cells. Programmed death receptor ligand 1 on melanoma cells negatively regulates T-cell function by binding to the programmed death-1 (PD-1) receptor on T cells. Antibodies against CTLA-4 and PD-1 also enhance the survival of melanoma patients. In this review, we summarize the clinical effectiveness and adverse events of the BRAF inhibitors, MEK inhibitors and anti-immune checkpoint antibodies in melanoma treatment.

元の言語英語
ページ(範囲)121-124
ページ数4
ジャーナルJournal of Dermatology
43
発行部数2
DOI
出版物ステータス出版済み - 2 1 2016

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Melanoma
CTLA-4 Antigen
Death Domain Receptors
Extracellular Signal-Regulated MAP Kinases
T-Lymphocytes
Therapeutics
Survival
Antibodies
Antigen-Presenting Cells
Disease-Free Survival
Cell Survival
Down-Regulation
Ligands
Drug Therapy
Mutation

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

Melanoma therapy : Check the checkpoints. / Furue, Masutaka; Kadono, Takafumi.

:: Journal of Dermatology, 巻 43, 番号 2, 01.02.2016, p. 121-124.

研究成果: ジャーナルへの寄稿評論記事

Furue, Masutaka ; Kadono, Takafumi. / Melanoma therapy : Check the checkpoints. :: Journal of Dermatology. 2016 ; 巻 43, 番号 2. pp. 121-124.
@article{a367af2d439a4b5fb526a0cff87e27f5,
title = "Melanoma therapy: Check the checkpoints",
abstract = "Recent mutational and translational studies have revealed that the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway plays a key role in melanomagenesis. Mutations in NRAS and BRAF are found in the majority of melanomas resulting in the formation of constitutively active NRAS and BRAF molecules, which leads to the proliferation and survival of melanoma cells through the activation of MEK/ERK signals. Inhibitors of BRAF or MEK significantly extend the progression-free survival and overall survival of melanoma patients compared with conventional chemotherapies. Combining BRAF and MEK inhibitors further enhances the clinical effectiveness. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is an immune checkpoint molecule that downregulates T-cell activation by binding to B7 (CD80/CD86) molecules on antigen-presenting cells. Programmed death receptor ligand 1 on melanoma cells negatively regulates T-cell function by binding to the programmed death-1 (PD-1) receptor on T cells. Antibodies against CTLA-4 and PD-1 also enhance the survival of melanoma patients. In this review, we summarize the clinical effectiveness and adverse events of the BRAF inhibitors, MEK inhibitors and anti-immune checkpoint antibodies in melanoma treatment.",
author = "Masutaka Furue and Takafumi Kadono",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/1346-8138.13257",
language = "English",
volume = "43",
pages = "121--124",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Melanoma therapy

T2 - Check the checkpoints

AU - Furue, Masutaka

AU - Kadono, Takafumi

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Recent mutational and translational studies have revealed that the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway plays a key role in melanomagenesis. Mutations in NRAS and BRAF are found in the majority of melanomas resulting in the formation of constitutively active NRAS and BRAF molecules, which leads to the proliferation and survival of melanoma cells through the activation of MEK/ERK signals. Inhibitors of BRAF or MEK significantly extend the progression-free survival and overall survival of melanoma patients compared with conventional chemotherapies. Combining BRAF and MEK inhibitors further enhances the clinical effectiveness. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is an immune checkpoint molecule that downregulates T-cell activation by binding to B7 (CD80/CD86) molecules on antigen-presenting cells. Programmed death receptor ligand 1 on melanoma cells negatively regulates T-cell function by binding to the programmed death-1 (PD-1) receptor on T cells. Antibodies against CTLA-4 and PD-1 also enhance the survival of melanoma patients. In this review, we summarize the clinical effectiveness and adverse events of the BRAF inhibitors, MEK inhibitors and anti-immune checkpoint antibodies in melanoma treatment.

AB - Recent mutational and translational studies have revealed that the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway plays a key role in melanomagenesis. Mutations in NRAS and BRAF are found in the majority of melanomas resulting in the formation of constitutively active NRAS and BRAF molecules, which leads to the proliferation and survival of melanoma cells through the activation of MEK/ERK signals. Inhibitors of BRAF or MEK significantly extend the progression-free survival and overall survival of melanoma patients compared with conventional chemotherapies. Combining BRAF and MEK inhibitors further enhances the clinical effectiveness. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is an immune checkpoint molecule that downregulates T-cell activation by binding to B7 (CD80/CD86) molecules on antigen-presenting cells. Programmed death receptor ligand 1 on melanoma cells negatively regulates T-cell function by binding to the programmed death-1 (PD-1) receptor on T cells. Antibodies against CTLA-4 and PD-1 also enhance the survival of melanoma patients. In this review, we summarize the clinical effectiveness and adverse events of the BRAF inhibitors, MEK inhibitors and anti-immune checkpoint antibodies in melanoma treatment.

UR - http://www.scopus.com/inward/record.url?scp=84956889299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956889299&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.13257

DO - 10.1111/1346-8138.13257

M3 - Review article

C2 - 26813076

AN - SCOPUS:84956889299

VL - 43

SP - 121

EP - 124

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 2

ER -